Study wrapper · #1362
Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis.
Editor's note
The effect sizes here are striking — arguably too striking, which is itself a caution: a 60% mortality reduction exceeds anything seen in randomized GLP-1 trials, suggesting residual confounding and healthy-user bias despite propensity matching. TriNetX gives scale but limited clinical granularity on disease severity and adherence. The direction of effect is consistent with STRIDE and the diabetic-PAD literature; the magnitude should await randomized confirmation in nondiabetic PAD.
Plain-language abstract
In a propensity-matched study of 27,110 US patients with peripheral artery disease and no diabetes, GLP-1 users had a 39% lower risk of major cardiovascular events, 60% lower all-cause mortality, and 78% fewer major limb events over five years; a sensitivity analysis limited to recent semaglutide starters showed similar results.